Su1650 Combined Biochemical and Clinical Markers in Bile Duct Obstruction: Novel Score for Prediction of Bile Duct Malignancy

adverse events rate and cholangitis risk was relatively less in phase II compared with that of phase I [(4.3% vs 10.3%; P Z .38) and (2.2% vs 4.5%; P Z .68)] respectively. On multivariate analysis for overall adverse events, only biliary sphincterotomy (odds ratio [OR] 5.04; 95% confidence interval [CI], 2.01-12.60; P Z .001) was associated with increased risk of adverse events. Bile aspiration prior to contrast injection did not impact the overall risk. (OR 0.51 (0.11 2.51); PZ .41). On multivariate analysis for development of cholangitis, only biliary stent placement (odds ratio [OR] 10.9; 95% confidence interval [CI], 1.3-92.7; PZ .03) was associated with increased risk of cholangitis. Although there was a trend, bile aspiration prior to contrast injection did not impact the overall risk of cholangitis. (OR 0.33 (0.04 2.87); PZ .32). Conclusion: An algorithmic approach to ERCP in PSC patients including bile aspiration is associated with a trend towards a decrease in the risk of overall adverse events and cholangitis. A larger sample size is required to reliably detect smaller differences.